Précis: 

Tube shunt implantation through the pars plana was effective for neovascular glaucoma (NVG) for at least 3 years, with few serious postoperative complications observed.

Purpose: 

The aim was to report 3-year outcomes of pars plana Ahmed and Baerveldt glaucoma implantation for NVG in Japanese eyes.

Patients and Methods: 

This study examined 41 eyes of 39 patients who underwent tube shunt implantation through the pars plana with the Baerveldt glaucoma implant (BGI group, 26 eyes) or Ahmed glaucoma valve (AGV group, 15 eyes) for NVG and who were followed up for over 3 years at Osaka Medical College between January 2009 and April 2016. Outcome measures were intraocular pressure (IOP, mm Hg) at presurgery and at 6 months and 1, 2, and 3 years postoperative. Postoperative failure was defined as an IOP of >21 mm Hg or <5 mm Hg, further glaucoma surgery, or no light perception.

Results: 

Mean IOPs at presurgery and at 3 years postoperative were 34.8±9.1 and 15.6±4.6 in the AGV group, and 36.9±9.2 and 12.8±5.5 in the BGI group. Mean antiglaucoma medication scores at 3 years postoperative were 1.3±1.4 in the AGV group and 0.4±0.8 in the BGI group (P=0.05). The number of eyes with a probability of failure at 6 months and at 2 and 3 years postoperative was 2, 3, and 4, respectively, in the BGI group, and 0, 1, and 2, respectively, in the AGV group.

Conclusion: 

Findings for NVG cases showed tube shunt implantation through the pars plana was effective. Equivalent good IOP reductions were noted in both groups, with the BGI group requiring fewer postoperative antiglaucoma medications compared with the AGV group. Furthermore, both groups exhibited few serious postoperative complications.

中文翻译：

---

Pars Plana Ahmed 和 Baerveldt 青光眼植入术治疗日本新生血管性青光眼的三年结果

概要： 

通过睫状体平坦部植入管分流术对新生血管性青光眼 (NVG) 有效至少 3 年，几乎没有观察到严重的术后并发症。

目的： 

目的是报告在日本人眼中植入 Ahmed 和 Baerveldt 青光眼 NVG 的 3 年结果。

患者和方法： 

本研究检查了 39 名患者的 41 只眼睛，这些患者接受了通过睫状体平坦部分流管植入Baerveldt 青光眼植入物（BGI 组，26 只眼）或 Ahmed 青光眼阀（AGV 组，15 只眼）进行 NVG，并随访了超过 3 年。 2009 年 1 月至 2016 年 4 月在大阪医学院学习数年。结果指标为术前、术后 6 个月以及术后 1、2 和 3 年的眼压（IOP，mm Hg）。术后失败定义为眼压>21毫米汞柱或<5毫米汞柱、进一步青光眼手术或无光感。

结果： 

AGV 组术前和术后 3 年的平均眼压分别为 34.8±9.1 和 15.6±4.6，BGI 组分别为 36.9±9.2 和 12.8±5.5。术后3年，AGV组平均抗青光眼药物评分为1.3±1.4，BGI组为0.4±0.8（P =0.05）。BGI组在术后6个月、术后2年和3年有失败可能性的眼睛数量分别为2、3和4只，AGV组分别为0、1和2只。

结论： 

NVG 病例的研究结果表明，通过平坦部植入管分流器是有效的。两组的眼压降低效果相当，与 AGV 组相比，BGI 组术后需要的抗青光眼药物更少。此外，两组均很少出现严重的术后并发症。